14 articles in this category
On February 12, 2015, a Philadelphia jury awarded a $3.6 million dollar verdict, which included a $1.3 million punitive damage award, to John Kristufek, a former Pennsylvanian educator, who alleged that pharma giant Takeda Pharmaceutical Co.’s Actos diabetes drug was the cause of his bladder cancer. Click here to read the full article: Takeda Ordered […]
After 34 days of trial, a Lafayette, Louisiana jury returned its verdict against Takeda and Lilly and ordered the PHARMA giants to pay $1.475 million in compensatory damages and $8 billion in punitive damages for injuries including bladder cancer to Terrance Allen, a hardware store manager, who took Actos for his diabetes treatment from 2004 […]
Terry Allen, a retired hardware store manager is the plaintiff in the case currently in trial against pharmaceutical giant Takeda, the manufacturer of Actos, the diabetes drug that Allen and his experts say caused him to have bladder cancer. (See In Re Actos (Pioglitazone) Products Liability Litigation, 11-md-02299; Allen’s case is Allen v. Takeda Pharmaceuticals […]
This week, Johnson & Johnson etched its name in the history books of another big pharma company that has been fined over billions of dollars due to a drug manufacturer practices of improper marketing and failure to warn. Johnson & Johnson pled guilty to claims stemming from allegations that the giant pharmaceutical company knowingly marketed […]
On September 26, 2013, a jury in Baltimore, Maryland, found that Takeda Pharmaceutical Co. did not properly warn Diep An, an ex-U.S. Army translator, and his doctor about the risks of its Actos diabetes drug and ordered the company to pay more than $1.7 million in damages. Jurors also found that An, a thirty year […]
Lawyers for the family of Diep An told a Baltimore jury that drug giant Takeda’s failure to tell the whole truth about Actos role in the increased risk of cancer was the cause of death, as opening statements got under way. This case will provide further insight into how a jury views Takeda’s role in […]
In 2012, Takeda’s profit dropped 53% and net profit was down 14% in the last nine months of 2012. Why? Because medical studies have demonstrated the causal connection between Takeda’s flagship diabetes drug Actos and bladder cancer and Takeda also lost its exclusivity patent on its foundation product diabetes treatment. Actos accounted for more than […]
Consumers injured by defective devices face an armada of attorneys as they seek to hold accountable device makers such as J&J’s hip implants DePuy ASR, DePuy Pinnacle, J&J’s transvaginal mesh product Ethicon, and Merck’s FOSAMAX that has left countless post menopausal women with atypical femur fractures. Currently there are over 10,000 pending cases in the […]
Overturning a recent $6.5 million dollar verdict for Plaintiff Jack Cooper in Cooper vs. Takeda (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court, Los Angeles), on May 1, 2013 the Hon. Kenneth Freeman granted two key Takeda’s motions leading to a reversal of the jury verdict of April 26, 2013. First, Judge Freeman […]
On April 26, 2013, a Los Angeles jury found Takeda liable for injuries including bladder cancer sustained by Jack Cooper, a former Pacific Bell telephone cable splicer, and returned a verdict of $6.5 million (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court, Los Angeles). The jury deliberated eight days after the conclusion of […]
Manufacturers, user facilities and importers of medical devices are mandated to submit certain adverse events to the U.S. Food and Drug Administration [FDA]. Medical device reporting requires that manufacturers report to the FDA when they learn that one of their devices may have contributed to a death or serious injury. Consumers and health professionals can […]
Takeda, who is defending itself in the Actos litigation where type 2 diabetics have higher than anticipated occurrence of bladder cancer, may be on the verge of another blockbuster drug gone awry. Recent reports in the Wall Street Journal indicate that the Takeda/Affymax anemia drug Omontys, which was approved by the FDA in April 2012, […]
The FDA approved Actos for treatment of diabetes in 1999, but complaints associated with bladder cancer have continued through the years. In August 2011, a report by eHealthMe based on FDA reports and the user community stated that of 22,512 people reporting side effects, 50 (0.22%) had bladder cancer. A May 2011 study of a […]
Although ACTOS is still being sold in the US, two leading European countries stopped sales of the drug. A June 2011 European clinical study by the French National Health Insurance plan found a statistically significant risk of bladder cancer among 1.5 million diabetic patients taking Actos, with the risk increasing for periods of treatment longer […]